Division of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Box 912, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.
Breast Cancer Res Treat. 2011 Oct;129(3):761-5. doi: 10.1007/s10549-010-1264-6. Epub 2010 Nov 27.
Biopsies of metastatic tissue are increasingly being performed. Bone is the most frequent site of metastasis in breast cancer patients, but bone remains technically challenging to biopsy. Difficulties with both tissue acquisition and techniques for analysis of hormone receptor status are well described. Bone biopsies can be carried out by either by standard posterior iliac crest bone marrow trephine/aspiration or CT-guided biopsy of a radiologically evident bone metastasis. The differential yield of these techniques is unknown. Results from three prospective studies of similar methodology were pooled. Patients underwent both an outpatient posterior iliac crest bone marrow trephine/aspiration and a CT-guided biopsy of a radiologically evident bone metastasis. Samples were assessed for the presence of malignant cells and where possible also for estrogen (ER) and progesterone receptor (PgR) expression. 40 patients were enrolled. Bone marrow aspiration/trephine biopsy was completed in 39/40 (97.5%) and CT-guided biopsy was completed in 34/40 (85%) of patients. Sufficient tumor cells for hormone receptor analysis were available in 19/39 (48.8%) and 16/34 (47%) of and bone marrow aspiration/trephine and CT-guided biopsies, respectively. Significant discordance in ER and PgR between the primary and the bone metastasis was also seen. Nine patients had tissue available from both bone marrow and CT-guided bone biopsies. ER and PgR concordance between these sites was 100 and 78%, respectively. Performing studies on human bone metastases is technically challenging, with relatively low yields regardless of technique. Given resource issues and similar success rates when comparing both techniques, bone marrow examination may be utilized first and if inadequate tissue is obtained, CT-guided biopsies can then be used.
越来越多的转移性组织进行活检。乳腺癌患者最常见的转移部位是骨骼,但骨骼在技术上仍然难以进行活检。组织获取和激素受体状态分析技术方面的困难已有详细描述。可以通过标准的髂后嵴骨髓活检/抽吸或 CT 引导的放射性骨转移灶活检进行骨活检。这些技术的差异产量未知。对具有相似方法的三项前瞻性研究的结果进行了汇总。患者接受了门诊髂后嵴骨髓活检/抽吸和 CT 引导的放射性骨转移灶活检。评估了样本中是否存在恶性细胞,以及在可能的情况下还评估了雌激素(ER)和孕激素受体(PgR)的表达。共纳入 40 例患者。骨髓抽吸/活检在 39/40 例(97.5%)患者中完成,CT 引导活检在 34/40 例(85%)患者中完成。在 19/39 例(48.8%)和 16/34 例(47%)的骨髓抽吸/活检和 CT 引导活检中,有足够的肿瘤细胞用于激素受体分析。还观察到原发性肿瘤和骨转移灶之间的 ER 和 PgR 存在明显不一致。9 例患者有来自骨髓和 CT 引导骨活检的组织。这些部位的 ER 和 PgR 一致性分别为 100%和 78%。对人类骨转移灶进行研究在技术上具有挑战性,无论采用哪种技术,其产量都相对较低。鉴于资源问题以及比较两种技术时成功率相似,骨髓检查可能首先进行,如果获得的组织不足,则可以使用 CT 引导活检。